Combined BRAF and HSP90 inhibition in patients with unresectable BRAF V600E mutant melanoma

PURPOSE: BRAF inhibitors are clinically active in patients with advanced BRAF(V600)-mutant melanoma, although acquired resistance remains common. Preclinical studies demonstrated that resistance could be overcome using concurrent treatment with the HSP90 inhibitor XL888. METHODS: Vemurafenib (960 mg...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Cancer Res
Asıl Yazarlar: Eroglu, Zeynep, Chen, Y. Ann, Gibney, Geoffrey T., Weber, Jeffrey S., Kudchadkar, Ragini R., Khushalani, Nikhil I., Markowitz, Joseph, Brohl, Andrew S., Tetteh, Leticia F., Ramadan, Howida, Arnone, Gina, Li, Jiannong, Zhao, Xiuhua, Sharma, Ritin, Darville, Lancia N.F., Fang, Bin, Smalley, Inna, Messina, Jane L., Koomen, John M., Sondak, Vernon K., Smalley, Keiran S.M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2018
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6195480/
https://ncbi.nlm.nih.gov/pubmed/29674508
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-0565
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller